{"title":"CCAR2通过正向调节SIRT1和激活Notch1/c-Myc通路驱动胶质瘤细胞存活。","authors":"Lan Ma, Chun Liu, Yi Zhang, Zhongjun Chen","doi":"10.1002/ddr.70159","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Cell cycle and apoptosis regulator 2 (CCAR2) is a transcriptional regulator involved in diverse types of cancer. However, its role in human glioma is unclear. This study aimed to investigate whether CCAR2 could function as a regulator in glioma. Database analysis results showed that CCAR2 expression was greatly higher in glioma tissues than that in control brain tissues. Besides, CCAR2 expression was upregulated in glioma cell lines. CCAR2 knockdown inhibited cell viability and proliferation and promoted apoptosis in glioma cells. The Notch1/c-Myc pathway was found to be inactivated by CCAR2 knockdown in glioma cells, while Notch1 overexpression reversed the inhibitory effect of CCAR2 knockdown on glioma cell survival. Further investigations showed that CCAR2 interacted with SIRT1 and regulated its expression. SIRT1 overexpression also attenuated the tumor-suppressing role of CCAR2 knockdown, as well as prevented CCAR2 knockdown-caused inactivation of Notch1/c-Myc pathway. Taken together, this study demonstrated that CCAR2 depletion exerted a tumor-suppressing role in glioma through regulating SIRT1-mediated Notch1/c-Myc pathway. These findings provide evidence for the therapeutic implication of CCAR2 in glioma treatment.</p></div>","PeriodicalId":11291,"journal":{"name":"Drug Development Research","volume":"86 7","pages":""},"PeriodicalIF":4.2000,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CCAR2 Drives Glioma Cell Survival by Positively Regulating SIRT1 and Activating the Notch1/c-Myc Pathway\",\"authors\":\"Lan Ma, Chun Liu, Yi Zhang, Zhongjun Chen\",\"doi\":\"10.1002/ddr.70159\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n <p>Cell cycle and apoptosis regulator 2 (CCAR2) is a transcriptional regulator involved in diverse types of cancer. However, its role in human glioma is unclear. This study aimed to investigate whether CCAR2 could function as a regulator in glioma. Database analysis results showed that CCAR2 expression was greatly higher in glioma tissues than that in control brain tissues. Besides, CCAR2 expression was upregulated in glioma cell lines. CCAR2 knockdown inhibited cell viability and proliferation and promoted apoptosis in glioma cells. The Notch1/c-Myc pathway was found to be inactivated by CCAR2 knockdown in glioma cells, while Notch1 overexpression reversed the inhibitory effect of CCAR2 knockdown on glioma cell survival. Further investigations showed that CCAR2 interacted with SIRT1 and regulated its expression. SIRT1 overexpression also attenuated the tumor-suppressing role of CCAR2 knockdown, as well as prevented CCAR2 knockdown-caused inactivation of Notch1/c-Myc pathway. Taken together, this study demonstrated that CCAR2 depletion exerted a tumor-suppressing role in glioma through regulating SIRT1-mediated Notch1/c-Myc pathway. These findings provide evidence for the therapeutic implication of CCAR2 in glioma treatment.</p></div>\",\"PeriodicalId\":11291,\"journal\":{\"name\":\"Drug Development Research\",\"volume\":\"86 7\",\"pages\":\"\"},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2025-09-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Development Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/ddr.70159\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Development Research","FirstCategoryId":"3","ListUrlMain":"https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/ddr.70159","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
CCAR2 Drives Glioma Cell Survival by Positively Regulating SIRT1 and Activating the Notch1/c-Myc Pathway
Cell cycle and apoptosis regulator 2 (CCAR2) is a transcriptional regulator involved in diverse types of cancer. However, its role in human glioma is unclear. This study aimed to investigate whether CCAR2 could function as a regulator in glioma. Database analysis results showed that CCAR2 expression was greatly higher in glioma tissues than that in control brain tissues. Besides, CCAR2 expression was upregulated in glioma cell lines. CCAR2 knockdown inhibited cell viability and proliferation and promoted apoptosis in glioma cells. The Notch1/c-Myc pathway was found to be inactivated by CCAR2 knockdown in glioma cells, while Notch1 overexpression reversed the inhibitory effect of CCAR2 knockdown on glioma cell survival. Further investigations showed that CCAR2 interacted with SIRT1 and regulated its expression. SIRT1 overexpression also attenuated the tumor-suppressing role of CCAR2 knockdown, as well as prevented CCAR2 knockdown-caused inactivation of Notch1/c-Myc pathway. Taken together, this study demonstrated that CCAR2 depletion exerted a tumor-suppressing role in glioma through regulating SIRT1-mediated Notch1/c-Myc pathway. These findings provide evidence for the therapeutic implication of CCAR2 in glioma treatment.
期刊介绍：
Drug Development Research focuses on research topics related to the discovery and development of new therapeutic entities. The journal publishes original research articles on medicinal chemistry, pharmacology, biotechnology and biopharmaceuticals, toxicology, and drug delivery, formulation, and pharmacokinetics. The journal welcomes manuscripts on new compounds and technologies in all areas focused on human therapeutics, as well as global management, health care policy, and regulatory issues involving the drug discovery and development process. In addition to full-length articles, Drug Development Research publishes Brief Reports on important and timely new research findings, as well as in-depth review articles. The journal also features periodic special thematic issues devoted to specific compound classes, new technologies, and broad aspects of drug discovery and development.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
